MAPT and Alzheimer disease: Plasma p-tau217 helps to differentiate AD from other neuropathological diseases (like FTLD), with a higher accuracy than plasma p-tau181 [146], plasma NfL, and MRI measures and shows almost equal efficacy compared with CSF p-tau and tau-PET [142].